According to the Centers for Disease Control and Prevention, antibiotic-resistant infections are associated with an additional 23,000 deaths and 2 million illnesses in the United States each year. The estimated annual impact of antibiotic-resistant infections on the national economy is $20 billion in excess direct health care costs, and as much as $35 billion in lost productivity from hospitalizations and sick days. By holding the Re-Entering Antibacterial Drug Development Summit, we at Cambridge Healthtech Institute are trying to contribute to the efforts to revive antibacterial pipeline, and to improve antimicrobial stewardship in the United States and worldwide. This Summit is designed as a forum for knowledge and opinion exchange between the major stakeholders, who are shaping the current state of antibacterial discovery and development.

Novel Monoclonal Antibodies for the Prevention and Treatment of Bacterial Infections.

Steven J. Projan. Ph.D., Senior Vice President, R&D, Innovative Medicines unit, Head of Infectious Diseases & Vaccines, Medimmune

Antibiotic Adjuvants To Reclaim Legacy Drugs

Gerard D. Wright, Ph.D., Director, Michael DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, Canada Research Chair in Molecular Studies of Antibiotics

Bringing The Full Power Of Chemical Synthesis To Bear On The Discovery Of New Antibiotics

Andrew G. Myers. Ph.D., Amory Houghton Professor of Chemistry, Department of Chemistry & Chemical Biology, Harvard University

Gram-Negative Antibiotics: The Importance Of Compound Properties For Drug Discovery

Heinz E. Moser, Ph.D., Executive Director – Chemistry Infectious Diseases, Global Discovery Chemistry, Novartis Institutes for BioMedical Research